These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 2432210)

  • 1. Acarboxy prothrombin (PIVKA-II) as a marker of hepatoblastoma in infants.
    Motohara K; Endo F; Matsuda I; Iwamasa T
    J Pediatr Gastroenterol Nutr; 1987; 6(1):42-5. PubMed ID: 2432210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S; Morishita T; Shibata J; Sato T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
    Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
    Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
    Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T
    Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma abnormal prothrombin (PIVKA-II): a new and reliable marker for the detection of hepatocellular carcinoma.
    Takikawa Y; Suzuki K; Yamazaki K; Goto T; Madarame T; Miura Y; Yoshida T; Kashiwabara T; Sato S
    J Gastroenterol Hepatol; 1992; 7(1):1-6. PubMed ID: 1371940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
    Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
    Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
    Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
    Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma.
    Grosley BM; Hirschauer C; Chambrette B; Bezeaud A; Amiral J
    J Lab Clin Med; 1996 Jun; 127(6):553-64. PubMed ID: 8648260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
    Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
    Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Sakon M; Monden M; Gotoh M; Kobayashi K; Kanai T; Umeshita K; Endoh W; Mori T
    Am J Gastroenterol; 1991 Mar; 86(3):339-45. PubMed ID: 1705389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal prothrombin: evaluation as a tumour marker and localization in tissues of patients with hepatocellular carcinoma.
    Koda T; Yamazaki S; Tamura I; Nakaba H; Takao T; Katayama S; Kurimura O
    J Gastroenterol Hepatol; 1993; 8(3):212-6. PubMed ID: 7686054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
    Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
    Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
    J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acarboxy prothrombin (PIVKA-II) in cord plasma in the south of Thailand.
    Laosombat V; Kenpitak K; Wongchanchailert M; Wiriyasateinkul A
    J Med Assoc Thai; 1993 May; 76(5):278-84. PubMed ID: 8006559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Studies of vitamin K sensitivity of PIVKA-II in patients with hepatocellular carcinoma].
    Furukawa M; Nakanishi T; Okuda H; Obata H
    Nihon Shokakibyo Gakkai Zasshi; 1988 Dec; 85(12):2583-9. PubMed ID: 2854170
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
    Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.
    Kawaguchi Y
    Jpn J Surg; 1989 May; 19(3):296-300. PubMed ID: 2550692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
    Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
    Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.